Moderna has seen mixed results recently, with various developments in its COVID-19 vaccine portfolio. FDA has granted approval for their newly introduced vaccine mNEXSPIKE, targeted primarily at adults 65 and older, and high-risk individuals aged 12 to 64; however, there are restrictions on its use. In a surprising turn of events, Moderna received court clearance on its COVID patent claims, dismissing a challenge from Alnylam.
Despite positive test results reported by Moderna for its bird flu vaccine, the US Department of Health and Human Services (HHS) has cancelled multiple contracts amounting to $766 million. The government's contract cancellation is noted despite the growing threat of bird flu. In response, the company has agreed to conduct a true placebo-controlled trial for its new COVID vaccine.
Interestingly, Moderna has also begun a Phase 1 study on a novel cancer therapy candidate. Meanwhile, its stock encounters fluctuation with some up and down trades. Despite the challenges, some investors view Moderna as a strong growth stock for long-term holdings.
Moderna MRNA News Analytics from Fri, 25 Oct 2024 07:00:00 GMT to Sat, 07 Jun 2025 13:15:15 GMT - Rating 3 - Innovation 3 - Information 7 - Rumor -4
